European Heart Journal

PDAY risk score predicts cardiovascular events in young adults: the CARDIA study.  43:2892-2900. 2022

Lung function impairment and risk of incident heart failure: the NHLBI Pooled Cohorts Study.  43:2196-2208. 2022

Alirocumab after acute coronary syndrome in patients with a history of heart failure.  43:1554-1565. 2022

Effects of dapagliflozin on mortality in patients with chronic kidney disease: A pre-specified analysis from the DAPA-CKD randomized controlled trial.  42:1216-1227. 2021

Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering:ODYSSEY OUTCOMES trial.  41:4245-4255. 2020

Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: Prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial.  41:4114-4123. 2020

Salt and cardiovascular disease: Insufficient evidence to recommend low sodium intake.  41:3363-3373. 2020

Hypertensive coronary microvascular dysfunction: A subclinical marker of end organ damage and heart failure.  41:2366-2375. 2020

Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: An ODYSSEY OUTCOMES trial analysis.  41:2248-2258. 2020

Comparative effectiveness of allopurinol and febuxostat for the risk of atrial fibrillation in the elderly: A propensity-matched analysis of Medicare claims data.  40:3046-3054. 2019

Effects of alirocumab on types of myocardial infarction: Insights from the ODYSSEY OUTCOMES trial.  40:2801-2809. 2019

Cardiovascular outcome trials in patients with chronic kidney disease: Challenges associated with selection of patients and endpoints.  40:880-886. 2019

Outcomes of transcatheter mitral valve replacement for degenerated bioprostheses, failed annuloplasty rings, and mitral annular calcification.  40:441-451. 2019

Associations between very low concentrations of low density lipoprotein cholesterol, high sensitivity C-reactive protein, and health outcomes in the Reasons for Geographical and Racial Differences in Stroke (REGARDS) study.  39:3641-3653. 2018

Take a blood pressure pill or benefit from renal denervation?.  39:3010-3012. 2018

Final Farewell to Alberto Zanchetti MD..  39:2616-2617. 2018

The circadian clock in cardiovascular regulation and disease: Lessons from the Nobel Prize in Physiology or Medicine 2017.  39:2326-2329. 2018

Acellular therapeutic approach for heart failure: In vitro production of extracellular vesicles from human cardiovascular progenitors.  39:1835-1847. 2018

Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials.  39:1687-1697. 2018

International recommendations for electrocardiographic interpretation in athletes.  39:1466-1480. 2018

Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction.  39:840-849. 2018

The consensus of the Task Force of the European Society of Cardiology concerning the clinical investigation of the use of autologous adult stem cells for the treatment of acute myocardial infarction and heart failure: Update 2016.  38:2930-2935. 2017

Global position paper on cardiovascular regenerative medicine.  38:2532-2546. 2017

The technical report on sodiumintake and cardiovascular disease in low- and middleincome countries by the joint working group of theWorld Heart Federation, the European Society of Hypertension and the European Public Health Association.  38:712-719. 2017

Comparative efficacy of coronary artery bypass surgery vs. percutaneous coronary intervention in patients with diabetes andmultivessel coronary artery disease with or without chronic kidney disease.  37:3440-3447. 2016

Valvular heart disease in older adults: Seeking an ounce of prevention.  37:3523-3524. 2016

Cardiac structure and function and leisure-time physical activity in the elderly: The Atherosclerosis Risk in Communities Study.  37:2544-2551. 2016

The TACTICS initiative: Time for a Global Alliance on Cardiovascular Regenerative Medicine.  37:2208-2211. 2016

CardioPulse. The SPRINT trial results.  37:924-927. 2016

The SPRINT trial results.  37:925-927. 2016

Regional cardiac dysfunction and outcome in patients with left ventricular dysfunction, heart failure, or both after myocardial infarction.  37:466-472. 2016

Mechanical Dyssynchrony: A Risk Factor but not a Target.  37:60-62. 2016

Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: First clinical case report.  36:2011-2017. 2015

Alcohol consumption and risk of heart failure: The Atherosclerosis Risk in Communities Study.  36:939-945. 2015

Function over form? Assessing the left atrium in heart failure.  36:711-714. 2015

Towards a clinical use of human embryonic stem cell-derived cardiac progenitors: A translational experience.  36:743-750. 2015

Effect of imatinib as add-on therapy on echocardiographic measures of right ventricular function in patients with significant pulmonary arterial hypertension.  36:623-631. 2015

Predictors of blood pressure response in the SYMPLICITY HTN-3 trial.  36:219-227. 2015

Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction.  35:3442-3451. 2014

Heart failure with preserved ejection fraction: A forest of a variety of trees.  35:3410-3412. 2014

A rare coronary anomaly: Origin of the right coronary artery from the left ventricular outflow tract.  35:2811. 2014

Combined intracardiac and epicardial device closure of a large left ventricular pseudoaneurysm.  35:2031. 2014

Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48.  35:1457-1465. 2014

Left ventricular dyssynchrony in patients with heart failure and preserved ejection fraction.  35:42-47. 2014

Prevention of liver cancer cachexia-induced cardiac wasting and heart failure.  35:932-941. 2014

Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: Findings from post hoc propensity-matched analysis of the AFFIRM trial.  34:1489-1497. 2013

Effect of antihypertensive therapy on ventricular-arterial mechanics, coupling, and efficiency.  34:676-683. 2013

Third universal definition of myocardial infarction.  33:2551-2567. 2012

Phenotypic and pathophysiological heterogeneity in heart failure with preserved ejection fraction..  33:1716-1717. 2012

Physiological concentration of glutamine increases exogenous fatty acid utilization in the ex vivo working heart: role of the hexosamine biosynthetic pathway.  32:1003-1003. 2011

Relationship between improvement in left ventricular dyssynchrony and contractile function and clinical outcome with cardiac resynchronization therapy: The MADIT-CRT trial.  32:1720-1729. 2011

Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction.  32:1227-1234. 2011

Hyperuricaemia, chronic kidney disease, and outcomes in heart failure: Potential mechanistic insights from epidemiological data.  32:712-720. 2011

Boomerang-shaped heart in isolated dextroversion.  32:247. 2011

A history of atrial fibrillation and outcomes in chronic advanced systolic heart failure: A propensity-matched study.  30:2029-2037. 2009

Fish consumption, marine omega-3 fatty acids, and incidence of heart failure: A population-based prospective study of middle-aged and elderly men.  30:1495-1500. 2009

Dipyridamole promotes ischemia-induced angiogenesis and tissue blood flow in critical limb ischemia througha PKA dependent nitric oxide pathway.  29:241-241. 2008

Erratum: ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary..  28:2046. 2007

A propensity-matched study of the association of low serum potassium levels and mortality in chronic heart failure.  28:1334-1343. 2007

Additive beneficial cardiovascular and metabolic effects of combination therapy with ramipril and candesartan in hypertensive patients.  28:1440-1447. 2007

ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation)..  27:1979-2030. 2006

Digoxin and reduction in mortality in systolic and diastolic heart failure at low serum digoxin concentrations [5].  27:1630. 2006

Heart failure, chronic diuretic use, and increase in mortality and hospitalization: An observational study using propensity score methods.  27:1431-1439. 2006

Persistent chest pain predicts cardiovascular events in women without obstructive coronary artery disease: Results from the NIH-NHLBI-sponsored Women's Ischaemia Syndrome Evaluation (WISE) study.  27:1408-1415. 2006

The consensus of the task force of the European Society of Cardiology concerning the clinical investigation of the use of autologous adult stem cells for repair of the heart.  27:1338-1340. 2006

Digoxin and reduction in mortality and hospitalization in heart failure: A comprehensive post hoc analysis of the DIG trial.  27:178-186. 2006

Skeletal myoblast transplantation through a catheter-based coronary sinus approach: An effective means of improving function of infarcted myocardium.  26:1551-1556. 2005

The deleterious effects of an irregular RR interval.  23:695-696. 2002

Hormone treatment - Misconceptions and agreements [4] (multiple letters).  23:89-91. 2002

Hormone treatment--misconceptions and agreements..  23:89-91. 2002

Early atrial defibrillation: 'A stitch in time saves nine' or 'haste makes waste'?.  22:1524-1526. 2001

Intravenous NPA for the treatment of infarcting myocardium early: InTIME-II, a double-blind comparison on of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction.  21:2005-2013. 2000

Simultaneous imaging of transmembrane potential and intracellular calcium in myocyte cultures.  21:549-549. 2000

Abciximab therapy in percutaneous intervention: economic issues in the United States..  19 Suppl D:D52-D58. 1998

Increased platelet activation and fibrinogen in Asian Indians. Potential implications for coronary risk.  19:720-726. 1998

Triiodothyronine therapy in open-heart surgery: From hope to disappointment.  14:629-633. 1993

Clinical use of automatic implantable defibrillators..  8 Suppl D:143-147. 1987

Clinical use of automatic implantable defibrillators.  8:143-147. 1987

Protective effects of cardioplegia on diastolic function of hypertrophied rat hearts after hypothermic ischaemic arrest..  5 Suppl F:347-353. 1984

Protective effects of cardioplegia on diastolic function of hypertrophied rat hearts after hypothermic ischaemic arrest.  5:347-353. 1984